PVT
Significant improvements in sustained attention/vigilance, as assessed by the PVT, were observed after danavorexton. For each endpoint, the values were averaged over the four time points post-infusion start. LS mean values for adjusted number of lapses were 3.38 and 2.52 for placebo and danavorexton, respectively, and the LS mean placebo-adjusted difference was −0.85 (95% CI: −1.3, −0.4; 